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In France, there are 35000 new cases of breast cancer each year.
There are various areas where clinical research is active, including
benign tumours and risk factors for malignant transformation,
biological evolution of normal and cancerous cells, prevention,
screening, diagnosis, therapeutic strategies, rehabilitation and
maintenance of quality of life.
This document concerns the diagnosis and therapeutic manage-
ment of nonmetastatic breast cancer, and does not cover screening
or prevention. This is a summary of an update (Mauriac et al,2 0 0 1 )
of the version published in 1996 (Mauriac et al, 1996), in which
sections concerning some particular situations and in situ carcino-
mas have not been included (these will be covered in a specific
document). In addition, breast cancer with a genetic predisposition
(BRCAX) will not be specifically covered in this document.
METHODS
The ‘Standards, Options and Recommendations’ (SOR) project,
which started in 1993, involves a collaboration between the
Federation of French Cancer Centres (FNCLCC), the 20 French
Regional Cancer Centres, several French public university and
general hospitals, private clinics and cancer-learned societies. The
main objective of the SOR project is to develop clinical practice
guidelines which can be used to improve the quality of health care
and outcomes for cancer patients. The methodology is based on a
literature review, followed by critical appraisal by a multi-
disciplinary group of experts to produce draft guidelines which
are then validated by specialists in cancer-care delivery. The details
of the methodology used for developing these SOR have been
described previously (Fervers et al, 2001).
A multidisciplinary working group was set up by the FNCLCC.
References to pertinent articles were identified by the global
bibliographic monitoring process of MEDLINE, set up in 1996 and
by specific searches in other databases such as Embase
s,
Cancerlit
s and the Cochrane Library
s, and from the personal
reference lists of the members of the working group. In addition,
the French National Agency for Health Accreditation and
Evaluation (ANAES) provided a complementary updated biblio-
graphic search (1999 to October 2000). After selection and critical
appraisal of these articles, the members of the working group
drafted the SORs.
‘Standards’ identify clinical situations for which there exist
strong indications or contraindications for a particular interven-
tion and ‘Options’ identify situations for which there are several
alternatives, none of which have shown clear superiority over the
others (Table 1). In any SOR, there can be several ‘Options’ for a
given clinical situation. ‘Recommendations’ enable the ‘Options’t o
be weighed according to the available evidence. Several interven-
tions can be recommended for the same clinical situation, so that
clinicians can make a choice according to specific clinical
parameters, for example, local circumstances, skills, equipment,
resources and patient preferences. Adapting the SORs to a local
situation is possible if the reason for the choice is sufficiently
transparent and this is crucial for successful implementation.
Inclusion of patients in clinical trials is an appropriate form of
patient management in oncology and is recommended frequently
within the SORs, particularly in situations where evidence is too
weak to support an intervention.
The type of evidence underlying any ‘Standard’, ‘Option’o r
‘Recommendation’, is indicated using a classification developed by
the FNCLCC based on previously published models. The level of
evidence depends not only on the type and quality of the studies
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www.bjcancer.comreviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgement is made
according to the professional experience and consensus of the
expert group (‘expert agreement’).
The document containing the SORs was then reviewed by a
group of independent experts (see the Appendix) and after taking
into consideration their comments, the guidelines were validated
by the working group.
This document summarises the key recommendations from the
complete updated edition that has been published in French as a
monograph (Mauriac, et al, 2001) and a French summary version
(Mauriac et al, 2002) and is also available at the Internet address:
http://www.fnclcc.fr.
CLINICAL DIAGNOSIS (FIGURES 1 AND 2)
Diagnostic work-up of an abnormality in the breast
Clinical examination In patients with locally and regionally
advanced disease, clinical examination is likely to be of greater
diagnostic value than in patients with less advanced disease
(standard). Tumours with the following characteristics are unlikely
to be operable, and are associated with a poor short-term
prognosis: inflammatory change, deep extension, lymphadeno-
pathy, breast oedema and/or lymphoedema in the upper limbs.
These factors also indicate an increased risk of locoregional and
metastatic recurrence (standard). Thus, nonoperability is not
always due to difficulties associated with the surgery itself. Surgery
may still be appropriate, however, to achieve local control, despite
a poor prognosis. Imaging can be used to confirm findings from
clinical examination. In some cases, clinical examination will be
normal, so that the diagnosis will only be possible following
imaging (standard).
Diagnostic imaging
A standard bilateral mammogram with two views (front and
external oblique), can be complemented by other views and by
ultrasonography (standard). The equipment used for mammogra-
phy should undergo regular quality control (standard). To confirm
the diagnosis, additional views and enlargements may be necessary
(option).
Specific imaging is not indicated in the examination of
lymphadenopathy. Standard reporting of mammograms should
Table 1 Definition of ‘Standards, Options and Recommendations’
Standards Procedures or treatments which are considered to be of benefit, inappropriate or harmful by unanimous decision based on the best available
evidence
Options Procedures or treatments which are considered to be of benefit, inappropriate or harmful by a majority, based on the best available evidence
Recommendations Additional information to enable the available options to be ranked using expect criteria (e.g. survival, toxicity) with an indication of the level of
evidence
Table 2 Definition of level of evidence
Level A
There exists a high standard meta-analysis or several high-standard randomised clinical trials which give consistent results
Level B
There exists good quality evidence from randomised trials (B1) or prospective or retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent when considered together
Level D
Either the scientific data does not exist or there is only a series of cases
Expert agreement
The data does not exist for the method concerned but the experts are unanimous in their judgement
Standard:
history, clinical examination and bilateral mammography
Option:
breast ultrasound
Suspicious
lesion(s)?
yes no
Standard:
no further investigation
and follow-up
Standard:
histological diagnosis *
Locally advanced
tumour?
yes
yes
no
no Positive metastatic
screen
Not applicable:
metastatic disease
not covered here
Treatment of palpable
breast cancers
Figure 7
* Results from cytology may be sufficient if primary surgery is planned.
Clinically detectable breast abnormality
Breast-conserving
surgery not possible
Figure 11
 
Figure 1 Diagnosis–clinically detectable breast abnormality.
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graphic features suspicious of malignancy using the American
College of Radiology classification (recommendation).
The diagnostic findings should be discussed by a multi-
disciplinary team. When the level of suspicion from imaging
justifies histological verification, this should be done using
interventional breast diagnostic techniques in an outpatient setting
under a local anaesthetic.
Pretreatment diagnosis
The diagnosis of malignancy can be obtained from cytology (fine-
needle aspiration) or tissue sample (core biopsy), whereas the
diagnosis of an invasive carcinoma can only be made from a
biopsy sample (standard).
The histological diagnosis of impalpable lesions should be
compared with the diagnostic hypotheses generated from diag-
nostic imaging (recommendation). The diagnosis of ductal
carcinoma in situ, lobular carcinoma in situ and atypical
hyperplasia from a needle biopsy sample should always be
reconfirmed using a sample obtained by surgical excision
(recommendation, level of evidence: B1). Regular assessment of
the diagnostic performance of image-guided biopsy systems is
recommended (recommendation, expert agreement).
PATHOLOGICAL EXAMINATION AND
CLASSIFICATION
Frozen sections
Examination of frozen sections is not indicated for isolated
clusters of microcalcification or for a tumour measuring less than
10mm (standard). It is indicated in other cases where it is likely to
modify the surgical plan (standard). This examination should not
jeopardise the quality of the excised sample and therefore the
reliability of the final histological diagnosis (standard).
Surgical margins
The standard histological report should mention the findings from
the diagnostic work-up and all factors necessary for establishing
the prognosis:
  the size of the malignant lesion(s) (in mm);
  the histological type;
  the histological grade (specifying the grading system used);
  the percentage of any ductal carcinoma in situ (DCIS);
  the presence of peritumoral vascular invasion;
  the status of the surgical margins, including that of all
additional excised samples.
For an invasive tumour, the measurement of the infiltrating
component should be given, including data from macroscopic and
microscopic examinations (recommendation). The overall size of
the lesions (including the invasive component and any associated
intraductal component) can be documented (option, expert
agreement).
If there is intraductal carcinoma only, the size of the lesions
should be assessed by combining the findings from the
radiological and histopathological examinations (recommenda-
tion). If this assessment is difficult (multiple foci, etc.), the number
of ‘positive’ sections out of the total number of sections examined
should be stated (recommendation, expert agreement).
The quality of the excised sample is defined by two criteria
(recommendation):
  the distance (in mm) between all malignant foci and the nearest
excision margin (identified using surgical guide marks);
  the nature of the tumour lesion (invasive or intraductal) nearest
to the surgical margin.
In cases where the surgical margin is invaded by tumour, the
extent of this should be specified (recommendation, expert
agreement).
Mastectomy
The standard histological report for a mastectomy sample should
state the details of the diagnostic work-up and those factors
required to establish the prognosis:
  the sites and number of malignant lesions;
  the size of the malignant lesions (in mm);
  the histological type of the tumour;
  the histological grade (specifying the grading system used);
  the percentage of DCIS, if present;
  the presence of peritumoral vascular invasion;
  the presence of extension into the nipple (specifying position
and type: intraductal, infiltrating, Paget’s disease);
  the presence if any of cutaneous or pectoralis major fasciomus-
cular involvement.
For an invasive tumour, the extent of the invasive component
should be given, integrating data from macroscopic and micro-
scopic examinations (recommendation). The overall extent of the
lesions (including the invasive component and any associated
intraductal component) can be documented (option, expert
agreement).
If there is intraductal carcinoma only, the size of the lesions
should be assessed by integrating the data from radiological and
microscopic examinations (recommendation). If this assessment is
difficult (multiple foci, etc.), the number of ‘positive’ sections out
of the total number of sections examined should be given
(recommendation, expert agreement).
Good quality
mammogram?
no
no
yes
yes Suspicious
abnormalities?
Treatment of impalpable
breast cancers
Figure 3
* MRI is under evaluation.
Impalpable mammographic abnormality
Standard:
history and clinical examination
Options*:
• additional views
• magnified views
• breast ultrasound
• radiologically guided core
  biopsy
Standard:
repeat bilateral mammography
Standard:
no further investigations 
Figure 2 Diagnosis–impalpable mammographic abnormality.
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All lymph nodes removed by axillary dissection should undergo
full histological examination using a series of macroscopic sections
(standard).
The standard histological report for the samples from axillary
dissection should specify:
  the number of lymph nodes examined;
  the number of metastatic lymph nodes, including the presence
of micrometastases and if a sentinel node biopsy was performed
before axillary dissection (standard);
  the number of metastatic lymph nodes with capsular rupture.
Optimal quality for axillary examination requires sampling
from at least 10 lymph nodes (standard, level of evidence: B1).
This is usually achieved by a level I/II axillary dissection (standard,
level of evidence: B1). Surgical guide marks should be
made to orientate the sample, at least at one end (standard).
The technique of sentinel node biopsy may avoid axillary
dissection in 85–90% of patients without lymph node involvement
(level of evidence: B1), but cannot be recommended until the
results of ongoing studies are available (recommendation, expert
agreement). This technique requires input from a multidisciplin-
ary team experienced in the area (recommendation, level of
evidence: B1).
Histological classification of breast cancer
The standard histological classification of breast cancer is that
developed by the World Health Organisation (WHO) (standard).
The standard for histo-prognostic grading is that developed by
Elston and Ellis (standard). This is applicable to all invasive
cancers with the exception of medullary carcinomas and in situ
carcinomas (standard). The coding of lesions can be performed
using the CIMO/SNOMED system (WHO classification) and/or the
ADICAP system (French classification) (option).
INVESTIGATIONS FOR THE DETECTION OF
METASTATIC DISEASE
There is no indication to undertake a metastatic screening before
the confirmation of a diagnosis of an invasive carcinoma
(standard). This is also true for in situ carcinomas (standard).
If a mastectomy is planned, a metastatic screening should be
performed prior to surgery to avoid unnecessary surgery in women
who already have metastatic disease, even if the probability is low
(recommendation). In the absence of symptoms, a metastatic
screening should only be performed after evaluation of the
metastatic risk factors (see section on Prognostic factors)
(recommendation). Assays of CA 15.3 and other tumour markers
should not be done during the initial work-up because of their low
sensitivity (standard, level of evidence: B2). At a more advanced
stage of disease, they are often elevated but have no diagnostic
value. Tumour markers can sometimes be used as a reference when
poor prognostic factors are present (option). No study has shown
an independent prognostic value for tumour markers. Nonspecific
markers, such as CA 125, CA19-9 and TPA, should not be assayed
(standard).
PROGNOSTIC FACTORS
Predictive factors for lymph node involvement
It is essential to perform a clinical examination of the axillary
region even though it is imprecise (standard, level of evidence: B1).
Lymph node involvement generally progresses towards the apex of
the axilla (standard, level of evidence: B1). Tumour size is the
principal risk factor for lymph node involvement (standard, level
of evidence: B1). Histologically confirmed axillary involvement,
tumour size and young age are the main predictive factors for
internal mammary node involvement (standard, level of evidence:
B2). The influence of the tumour site is controversial.
Predictive factors for local breast recurrence
The most important clinical factors are young age (under 35 or 40
years old) and premenopausal status. The most important
histological factors are: positive excision margins and the presence
of an extensive ductal in situ component associated with the
invasive component, high-grade tumour, the presence of peritu-
moral vascular invasion and inappropriate treatment.
Predictive factors for metastatic disease
The most important clinical factors are young age (under 35 or 40
years old), tumour size and axillary node involvement. The
histological factors with the strongest prognostic value are tumour
size, histologically confirmed node involvement, the number of
axillary nodes involved (X4), a high-grade tumour and positive
excision margins. The presence of peritumoral vascular invasion is
also a predictive factor for metastatic disease.
Predictive factors for therapeutic response
Hormone receptor status should be determined in all cases of
invasive disease (standard), using either a biochemical or
immunohistochemical method (standard). The analysis for over-
expression of c-erbB-2 should not be performed on a routine basis
(standard). The predictive factors for response to chemotherapy,
including c-erbB-2, are in the process of being evaluated. Cellular
proliferation should be assessed in all infiltrating tumours, using
either the mitotic index, S phase fraction measurement or Ki67
immunohistochemical assay (recommendation, expert agreement).
Quality control is mandatory in all laboratories irrespective of the
prognostic test performed (standard).
TREATMENT MODALITIES
Surgery
Irrespective of the surgical technique used, tumour excision
should be complete with negative margins and should be adapted
to the tumour size and the breast volume (standard). The optimal
size of excision to ensure negative margins has not been defined
(standard).
When breast-conserving surgery is to be undertaken, the
aesthetic result should be acceptable to the patient (standard).
Central tumours can be treated in a conservative manner if
excision is complete (sometimes requiring excision of the nipple–
areolar complex) (option).
Modified radical mastectomy is equivalent to radical mastect-
omy in terms of local control and survival (standard). Breast-
conserving treatments with lumpectomy followed by radiotherapy
are equivalent to mastectomy in terms of local recurrence and
survival (standard, level of evidence: A). Subcutaneous mastect-
omy should not be considered for invasive or noninvasive breast
cancer (recommendation, expert agreement).
Complications after axillary node dissection
There appears to be no technique available to assess the risk of
sequelae (particularly lymphoedema) following surgery to this
anatomically complex and strategic area where several different
lymphatic regions converge (back, legs, anterior thoracic wall and
breast). Early physiotherapy for the shoulder and the thoracic wall
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patients of the best means of prevention remains the best means of
preventing lymphoedema. Lymphatic drainage is not indicated as a
preventative measure (recommendation).
Radiotherapy
Radiotherapy reduces the risk of mortality due to breast cancer
(standard, level of evidence: A). However, it may increase the risk
of long-term cardiovascular mortality if an inappropriate techni-
que is used. Breast, chest wall or lymph node irradiation should be
performed with caution, with the aim of limiting the irradiation of
healthy tissue, while satisfying quality assurance criteria (stan-
dard). The dose prescription is standardised (the International
Commission on Radiation Units (ICRU)) (standard, level of
evidence: A).
After breast-conserving surgery, breast radiotherapy should
always be performed, using a minimum dose of 50Gy in 25
fractions (standard, level of evidence: A). Breast irradiation after
breast-conserving surgery significantly reduces the risk of local
recurrence irrespective of the initial disease stage (standard, level
of evidence: A). In women under 50 years old, a boost should be
administered routinely to the tumour bed even when the margins
are clear (standard, level of evidence: B). Guidelines from an expert
committee of the French Society of Oncological Radiotherapy
(SFRO, 1991) cover the choice of target volume for irradiation
following breast-conserving surgery. After mastectomy, the benefit
from chest wall radiotherapy is greater in patients with the highest
number of risk factors (standard, level of evidence: A).
Irradiation of the internal mammary lymph nodes is indicated
in all cases of axillary lymph node involvement (standard, level of
evidence: B1) and when the tumour is medial or central (standard,
expert agreement). Irradiation of the infra- and supraclavicular
lymph nodes is indicated in the presence of axillary lymph node
involvement (standard, level of evidence: B1). The omission of
lymph node irradiation, as defined above, is only justified in the
setting of a randomised clinical trial (standard, expert agreement).
The choice of immediate breast reconstruction should not
jeopardise the optimal use of locoregional radiotherapy and
systemic treatment (recommendation). After axillary dissection,
radiotherapy to the axilla should be avoided as much as possible
because of the increased risk of locoregional complications
(standard, level of evidence: C).
Chemotherapy
Anthracycline-containing polychemotherapy is currently the
most commonly used regimen in France and is more efficacious
than the CMF regimen: cyclophosphamide, methotrexate and
fluorouracil (5-FU) (standard, level of evidence: A). This is
supported by the conclusions from the NIH consensus conference
(NIH, 2000).
Adjuvant chemotherapy improves progression-free survival and
overall survival in patients with node-positive breast cancer and in
certain patients without node involvement. Premenopausal women
seem to benefit more than menopausal women.
Doxorubicin, epirubicin, 5-FU, cyclophosphamide and metho-
trexate used in combination every 3–4 weeks, with a maximum of
six cycles, is the reference treatment. The optimal number of cycles
(four to six cycles) is unknown. Chemotherapy should be started
promptly. The efficacy of perioperative chemotherapy has not been
clearly proved, and should only be undertaken in the setting of a
randomised clinical trial. High-dose chemotherapy, with or
without stem cell infusion, is under evaluation and cannot be
considered as a therapeutic standard. The optimal dose for
epirubicin remains to be determined. Taxanes have not yet been
shown to offer any benefit as adjuvant or neoadjuvant treatment.
Induction or neoadjuvant chemotherapy is an option in
operable breast cancer where first-line breast-conserving surgery
is not possible, in the absence of multifocal lesions, and where the
patient would prefer breast conservation (option). Compared with
adjuvant therapy, induction or neoadjuvant therapy has no effect
on survival but has been shown to avoid mastectomy in more than
50% of women. The risk of local recurrence is higher than with a
primary mastectomy and the possibility of breast-conserving
surgery is reduced. After neoadjuvant chemotherapy, locoregional
treatment should be performed in the same manner as that used
for first-line locoregional treatment (standard).
In premenopausal women, the combination of hormone therapy
with adjuvant chemotherapy does not lead to a significant
improvement in global survival or progression-free survival. This
may be due to the low number of young women treated with
tamoxifen and/or the lack of stratification for hormone receptor
status in previous studies (standard, level of evidence: A).
However, the practice was recommended in November 2000 by
the NIH consensus conference (NIH, 2000).
Hormone therapy
Treatment with adjuvant tamoxifen is beneficial, despite its side
effects, irrespective of the patients’ age, if the tumour expresses
oestrogen receptors (standard, level of evidence: A). Tamoxifen
should not be prescribed to women with tumours that do not
express oestrogen receptors (standard, level of evidence: A). The
optimal duration for adjuvant hormone therapy with tamoxifen is
5 years at a dose of 20mgday
 1 (standard, level of evidence: A).
Patients treated with tamoxifen should have regular gynaecological
clinical examinations (recommendation, expert agreement). Addi-
tional examinations are not necessary in the absence of symptoms.
Neoadjuvant treatment with antioestrogens can be used in
elderly women with slowly evolving hormone-sensitive tumours
(option, level of evidence: B1). This should be followed when
possible by optimal locoregional treatment (option, expert
agreement). At present, antioestrogens cannot be considered as
standard neoadjuvant treatment for initially operable tumours.
Hormone therapy can be administered for different reasons,
depending on the patients’ age:
  suppression of ovarian function in women with ovarian activity
and/or as an antioestrogen,
  antioestrogenic therapy in postmenopausal women.
In postmenopausal women, the combination of chemotherapy
with an antioestrogen significantly improves progression-free
survival and overall survival (standard, level of evidence: A). The
ratio of efficacy (overall or recurrence-free survival) and risk
(toxicity) should be considered when taking the decision to
prescribe this combination. The efficacy/risk ratio favours
treatment in women with major metastatic risk factors (recom-
mendation, expert agreement).
Other hormone therapy (progestogens, aromatase inhibitors)
should not be considered as adjuvant treatments except in the
setting of a randomised clinical trial (standard).
Breast reconstruction and additional treatments
When mastectomy is necessary to obtain local control and the
patient would prefer immediate breast reconstruction, multi-
disciplinary consultation is essential to assess the need for
locoregional (irradiation) or systemic (chemotherapy or hormone
therapy) treatment. Breast reconstruction is not a cancer treatment
but is an integral component of breast cancer care (standard). It
can be performed immediately or be delayed, but should never
interfere with the administration of other treatments (chemother-
apy and/or radiotherapy) (standard). Poor prognosis is not a
contraindication for breast reconstruction (standard). However,
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of the disease can be relative contraindications (standard).
The patient should participate in the final decision (standard).
There are three main techniques for reconstruction: submuscular
inplant, latissimus dorsi flap or TRAM (transverse rectus
abdominis myocutaneous) pedicle flaps and microanastomosed
free flaps (option).
If the patient requires radiotherapy but wants immediate breast
reconstruction, autologous tissue techniques should be used. A
prosthesis can be irradiated but the patient should be informed
about the potential risks, particularly that of substantial contrac-
tion as seen in about 50% of patients.
TREATMENT STRATEGY
The patient should participate in her treatment decisions at every
stage.
Treatment evaluation
Treatment evaluation involves both functional and aesthetic
evaluation, consideration of possible side effects and the patients’
quality of life (standard). Painful scarring (leading to limited
mobility of the arm/shoulder) and lymphoedema are the most
frequently observed complications after surgery. The aesthetic
result depends on the quality of the surgery and radiotherapy
technique (standard). Aesthetic problems do not occur following
chemotherapy alone, but are observed when chemotherapy is used
concomitantly with radiotherapy (standard). Visual analogue
scales of well being are useful for assessing quality of life. Fatigue
has a significant impact on quality of life and can be related to
treatment and/or a depressive reaction. This should always be
taken into consideration by the physician and its importance
should not be underrated. Questionnaires exist for assessing
fatigue and quality of life (standard).
Locoregional treatment
Surgery and/or radiotherapy are used for the locoregional control
of the disease.
Management of impalpable tumours The therapeutic strategy for
ductal carcinomas in situ is not covered in this document. The
therapeutic management of impalpable tumours is often a stepwise
process guided by the histological results of the previous
intervention. The patient should be informed right from the start
about the risks associated with repeated interventions.
  First decisional step (Figure 3): This first step is diagnostic and
potentially therapeutic and consists of a radiologically proven
complete excision and histological analysis of the lesion
(standard). In the absence of a palpable macroscopic lesion, a
frozen section and primary axillary dissection should not be
performed (recommendation, expert agreement). If microcalci-
fications are present, a mammogram should be performed 2
months after surgery (recommendation, expert agreement).
  Second decisional step: This step depends on the status of the
surgical margins and the extent of the microcalcification before
and/or after surgery.
* Microinvasive cancer (infiltrating component p2mm): There
is no specific data concerning the risk of progression of
microinvasive cancers. The recommendations are the same as
those proposed for invasive cancers (Figure 4).
— Extensive microcalcifications at diagnosis (breast-conser-
ving surgery inappropriate): Modified radical mastectomy
followed by immediate breast reconstruction should be
offered (standard).
— Clear margins and no residual microcalcifications: The
breast should be irradiated (standard). Modified radical
mastectomy can be considered if the patient refuses
conservative treatment (option). Axillary dissection or
axillary radiotherapy may also be performed (option). In
the absence of known risk factors for metastatic
recurrence, adjuvant systemic treatment should not be
given (recommendation, level of evidence: B).
— Involved margins and/or residual microcalcifications:
Mastectomy is the standard treatment (standard). Re-
excision and breast radiotherapy, or axillary dissection
and radiotherapy can be performed (option). If re-
excision does not provide clear margins, mastectomy
should be performed (standard).
* Invasive cancer (Figure 5):
— Extensive micro-calcifications at diagnosis: Modified
radical mastectomy is indicated (standard). In the event
of lymph node invasion, radiotherapy to the chest wall
and lymph nodes (internal mammary chain, infra- and
supraclavicular) should be performed (standard).
— Clear margins and/or absence of residual microcalcifica-
tions: The standard procedure is axillary dissection and
breast radiotherapy (standard). If the patient presents
with lymph node involvement, this should be followed by
lymph node irradiation (internal mammary chain, infra-
and supraclavicular) (standard). It is also possible to
irradiate the lymph nodes without axillary surgery
(option).
— Invaded margins and/or presence of residual microcalci-
fications: Modified radical mastectomy should be per-
formed (standard). In the event of lymph node
involvement, this should be followed by the chest wall
and lymph nodes (internal mammary chain, infra- and
supraclavicular) irradiation (standard). Re-excision com-
bined with axillary dissection, followed by breast
radiotherapy can be undertaken. Breast radiotherapy
with a boost to the tumour bed can also be considered
(option).
Invasive carcinoma
2nd decision step
Figure 5
Microinvasive cancer
2nd decision step
Figure 4
*      Preoperative diagnosis of an invasive lesion by core biopsy will allow immediate
       investigation for axillary node involvement (see Figure 10: 3rd decision step)
**     If microcalcifications present
***   Carcinomas in situ have not been included here and will be treated in a specific document
Microinvasive cancer
Impalpable breast tumour
1st decision step
Standard:
excision*
+ imaging of surgical sample
+ histopathological analysis
+ postoperative mammography **
Invasive carcinoma
Histological type ***?
 
Figure 3 Impalpable operable tumour–locoregional treatment.
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breast-conserving surgery A single palpable localised tumour can
be completely excised with a wide margin (Figure 6). This is
dependent on the probability of achieving an excision with clear
margins and a satisfactory aesthetic result.
  First decision step (Figure 7): Lumpectomy (7frozen section),
axillary dissection and breast radiotherapy is the standard. The
breast should always be irradiated; this has been shown to
reduce considerably the rate of local recurrence (recommenda-
tion, level of evidence. A). Axillary dissection should only be
undertaken after the diagnosis of an invasive carcinoma has
been confirmed (recommendation, expert agreement). It is
essential to examine all tissue margins (recommendation).
Central tumours can be managed with conservative treatment
(recommendation, expert agreement). If the patient refuses
conservative treatment, a modified radical mastectomy can be
considered (option). If microcalcifications are present, a post-
operative mammogram is essential to verify the presence or
absence of residual lesions after conservative treatment
(standard, expert agreement).
  Second decision step (Figure 8): This step follows conservative
treatment and depends on the histological status of the tissue
margins and the presence of other risk factors.
* Clear excision margins (Figure 8): Whole breast radiotherapy
should be performed (standard) with an additional dose to
the tumour bed (boost) if the patient is under 50 years old
(standard). This association can be given to patients over 50
years old who have other risk factors for recurrence (option).
* Positive excision margins (Figure 9).
— When re-excision is possible (histologically clear margins
possible and a satisfactory aesthetic result). The standard
procedure is to undertake re-excision and breast radio-
therapy (standard). This should be followed by a boost to
the tumour bed if the patient is under 50 years old
(standard) or has other risk factors (option).
If a boost to the tumour bed and/or re-excision is
performed, the aesthetic result should be satisfactory
(recommendation, expert agreement). If the patient
refuses re-excision, breast radiotherapy with a boost to
the tumour bed can be considered (option). Modified
radical mastectomy can also be considered (option).
Microinvasive cancer
2nd decision step
Widespread
microcalcifications?
yes no
no yes Involved margins and/or
presence of residual
microcalcifications?
Standard:
•  modified radical
   mastectomy
•  immediate breast
   reconstruction if
   patient's preference
Options:
delayed breast
reconstruction
Standard:
breast radiotherapy
Options:
•  modified radical mastectomy if
   breast-conserving treatment 
   refused
• axillary dissection
•  if no axillary dissection, axillary
   radiotherapy
• no treatment to the axilla
Standard:
mastectomy
Options:
•  re-excision* and breast radiotherapy
•  axillary dissection
•  if no axillary dissection, axillary,
   internal mammary, and infra/supra-
   clavicular radiotherapy
•  no treatment to the axilla
If dissection was performed:
3rd decision step
Figure 10
Indications for
adjuvant treatment
Figure 15
Indication for
adjuvant treatment
Figure 15
Indication for nodal
radiotherapy
3rd decision step
Figure 10
* To obtain clear margins
Figure 4 Operable impalpable tumour–locoregional treatment.
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involved after re-excision, and/or the aesthetic result will
not be satisfactory). Modified radical mastectomy should
be performed (standard). Immediate breast reconstruc-
tion can be considered if there are no other risk factors
for locoregional recurrence and/or this does not
prejudice the administration of additional treatment
(option).
If the patient refuses mastectomy and there is a high risk of
metastatic recurrence or if there is minimal invasion of the excised
tissue margins, breast radiotherapy and a boost to the tumour bed
can be proposed (option, level of evidence: D).
  Third decision step (Figure 10): This depends on the extent of
axillary node involvement.
* Absence of axillary node involvement: The decision depends
on the tumour localisation.
— Lateral tumour The nodal areas should not be irra-
diated (standard).
— Central and/or medial tumour The internal mammary
chain should be irradiated (standard). Infra- and
supraclavicular radiotherapy can also be considered
(option). Nodal irradiation for low-risk tumours is not
recommended, and is currently under evaluation.
Irrespective of the tumour localisation, axillary radio-
therapy should not be performed in the absence of
Widespread
microcalcifications?
no yes
Indications for nodal
radiotherapy
3rd decision step
Figure 10
Indications for nodal
radiotherapy
3rd decision step
Figure 10
Indications for nodal
radiotherapy
3rd decision step
Figure 10
Standards:
• modified radical mastectomy
• chest wall radiotherapy if risk
   factors present
Options:
• re-excision
   and breast radiotherapy
   ± boost to tumour bed
• axillary dissection
• if no axillary dissection,
   axillary radiotherapy
Standard:
axillary dissection
and breast radiotherapy
Standards:
• modified radical
  mastectomy
• chest wall radiotherapy if
  risk factors present
Invasive carcinoma
2nd decision step
Positive margins and/or
presence of residual
microcalcifications?
no yes
Figure 5 Operable impalpable tumour–locoregional treatment.
Operable palpable breast tumour
Single localised tumour that can be
completely excised (histologically) with a
satisfactory aesthetic result?
yes no
Breast-conserving
surgery possible
Figure 7
Breast-conserving surgery
not possible
Figure 11
Figure 6 Operable palpable tumour–locoregional treatment.
Palpable breast tumour
breast-conserving surgery possible
1st decision step
Breast cancer after initial
breast-conserving surgery
2nd decision step
Figure 8
* A frozen section can be avoided if there is prior histological evidence 
 of an invasive carcinoma.
Standard:
lumpectomy
± frozen section *
+ axillary dissection
+ breast radiotherapy
Option:
modified radical mastectomy if patient's preference
Breast-conserving
surgery not possible
Figure 11
Figure 7 Operable palpable tumour–locoregional treatment.
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tion, level of evidence: A).
* Presence of axillary node involvement: Screen for distant
metastases (standard) and irradiate infra- and supraclavicu-
lar plus internal mammary nodes (standard). If extensive
nodal involvement is present, the whole of the axillary region
can be irradiated (option). Radiotherapy should only be
omitted in the setting of a randomised clinical trial (option).
Palpable tumour, primary breast-conserving surgery not possible
  First decision step: A metastatic screen should be undertaken
(standard) (Figure 11). A modified radical mastectomy should
be performed in the absence of metastases (standard).
Nonsurgical treatment (medical or radiotherapy) can be
considered (option). Nonsurgical treatment is not indicated
for multifoci lesions where the local treatment should be
mastectomy (recommendation, expert agreement). If primary
radiotherapy or medical treatment is performed, locoregional
control must be obtained (recommendation, level of evidence:
A) (Figure 12).A preliminary biopsy can be performed to assess
the prognostic factors that are necessary to guide locoregional
and adjuvant treatment (recommendation, expert agreement).
When immediate reconstruction is offered, it should not
jeopardise the administration of locoregional and/or systemic
treatment (recommendation).
  Second decision step (Figure 13): This step occurs after
mastectomy and axillary dissection and is dependent on the
presence or absence of risk factors for local recurrence.
* Absence of risk factors for local recurrence: Chest wall
radiotherapy is not indicated (standard).
* Presence of risk factors for local recurrence: Chest wall
radiotherapy is indicated (standard).
  Third decision step (Figure 10): This step is dependent
on the extent of axillary node involvement (see section
on ‘Management of a single palpable localised tumour
treatable by breast-conserving surgery, third decision
step’).
Adjuvant therapy (Figure 14)
The aim of adjuvant therapy is to reduce the risk of metastatic
recurrence and thus improve survival. Risk factors for metastatic
recurrence should be assessed during the initial examination and
*Risk factors: age<50 years old; lymph node involvement; vascular invasion;
 grade III tumour; high mitotic index; negative hormone receptors
Clear margins? yes no
Breast cancer after primary breast-conserving surgery
2nd decision step
yes no Risk factors* for local
recurrence?
Breast cancer after primary
breast-conserving surgery
2nd decision step
positive margins
Figure 9
Indication for nodal
radiotherapy 
3rd decision step
Figure 10
Breast cancer after primary
breast-conserving surgery
2nd decision step
clear margin(s) and other risk
factor(s) for local recurrence
Figure 5
Standards:
•  breast radiotherapy
•  boost if patient<50 years
Options:
• boost if patient>50 years
   and other risk factors
   present
• mastectomy if other
   risk factors present
Figure 8 Operable palpable tumour–locoregional treatment.
yes
yes
no
no
*   For an infiltrating duct or in situ tumour.
** Possibility of obtaining histologically clear margins and a satisfactory aesthetic result.
Breast cancer after primary breast-conserving surgery
2nd decision step
positive margins*
Breast cancer after primary
breast-conserving surgery
2nd decision step
Figure 8
Indications for nodal
radiotherapy
3rd decision step
Figure 10
Standard:
modified radical mastectomy
Options:
• immediate breast reconstruction if no other
   risk factor(s) for locoregional recurrence
   and/or this will not jeopardise the
   administration of additional treatments
• breast radiotherapy and boost to tumour bed
   if mastectomy refused or  when the risk of
   local recurrence is accompanied with the risk
   of metastatic recurrence or minimally positive
   excision margins
Re-excision possible?**
Clear margins?
Figure 9 Operable palpable tumour–locoregional treatment.
Indication for nodal radiotherapy
3rd decision step
Axillary node
involvement?
yes no
Tumour
location?
Central and/or
medial tumour
Indication for
adjuvant treatment
Figure 15
Indication for
adjuvant treatment
Figure 15
Indication for
adjuvant treatment
Figure 15
Standards:
•  perform metastatic assessment
•  radiotherapy (infra/supraclavicular
   and internal mammary chain)
Options:
•  irradiation of the whole of the axilla
    if major node involvement
•  no irradiation of lymph nodes
    except in the setting of a
    prospective clinical trial
Standards:
   radiotherapy to the internal mammary
   chain
Options:
•  infra/supraclavicular radiotherapy
•  no node radiotherapy for lesions thought
   to be low risk (under evaluation)
Lateral tumour
Standard:
no radiotherapy to
nodes
Figure 10 Operable tumour–indication for nodal radiotherapy.
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Adjuvant therapy should not replace optimal locoregional treat-
ment. The patient’s menopausal status and the tumour hormone
receptor status should be used in the selection of one of the
reference treatments: hormone therapy and/or chemotherapy.
Adjuvant therapy after surgery and initial axillary dissection
with the possibility of breast conservation The standards, options
and recommendations are summarised in Tables 3 and 4 and
Figures 15–18.
Adjuvant therapy after first-line chemotherapy or hormone
therapy There is no standard treatment. Hormone therapy with
tamoxifen can be given if the tumour is positive (or unknown) for
oestrogen receptors (option) (Figure 19).
Adjuvant therapy after first-line radiotherapy The size of the
initial lesion may justify the use of adjuvant medical therapy
(recommendation) (Figure 20).
FOLLOW-UP
Follow-up should focus on the evaluation of the treatment results,
screening for relapse, treatment of side effects and psychosocial
and professional rehabilitation (Figure 21). This requires a
multidisciplinary approach.
Follow-up of the conserved breast
Clinical examination should be performed 4 months after
treatment to assess treatment toxicity (standard). Clinical follow-
up should then be repeated every 6 months for 5 years and then
yearly for 10 years (standard). Routine follow-up should be
continued after 10 years, but the timing can be adjusted depending
on the risk of local recurrence (option). An annual mammogram
should be performed starting 6 months after treatment (standard).
Distant metastases
present?
yes
yes
yes
no
no
no
Premenopausal woman
or 50 years?
ER+ve*?
Local treatment
(Figures 12 and 20)
*ER+ve, presence of oestrogen receptors.
Operable tumour but breast
conservation not possible
1st decision step
Standard:
• assessment for distant
  metastases
Not  applicable:
metastatic disease not
covered here
Standard:
•   modified radical mastectomy
Options:
•   neoadjuvant chemotherapy
•   neoadjuvant  radiotherapy
Standard:
•   modified radical mastectomy
Options:
•   neoadjuvant chemotherapy
•   neoadjuvant  radiotherapy
Standard:
•   modified radical mastectomy
Options:
•   neoadjuvant hormone therapy
•   neoadjuvant chemotherapy
•   neoadjuvant  radiotherapy
Local treatment
Figures 12 and 20
Local treatment
Figures 12 and 20
Local treatment
Figures 12 and 20
Figure 11 Palpable tumour, breast-conserving surgery not possible.
Local treatment after neoadjuvant radiotherapy
Standard:
there is no standard
Options:
•  breast-conserving surgery
•  modified radical mastectomy
•  radiotherapy only 
Adjuvant medical
treatment
Figure 20
Figure 12 Palpable tumour, breast-conserving surgery not possible–
local treatment after neoadjuvant radiotherapy.
Breast cancer after modified radical mastectomy
2nd decision step
yes no Presence of risk factors for local
recurrence?
Indication for nodal
radiotherapy
3rd decision step
Figure 10
Indication for nodal
radiotherapy
3rd decision step
Figure 10
Standard:
chest wall radiotherapy
Standard:
no chest wall radiotherapy
Figure 13 Palpable tumour, breast-conserving surgery not possible:
modified radical mastectomy.
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Routine clinical examination forms the basis of follow-up for the
thoracic wall and the lymph node areas after treatment for breast
cancer.
Follow-up of the contralateral breast
Clinical examination and a mammogram should be performed at
the same frequency as above for the follow-up of the conserved
breast (standard, expert agreement).
General follow-up after treatment of patients in complete
remission
History taking and clinical examination form the basis of follow-
up (standard). In the absence of symptoms or signs, a routine
screen for metastases is not indicated (standard, level of evidence:
A). If a metastasis is found, the patient should undergo a full work-
up (recommendation, expert agreement). The frequency of general
clinical follow-up is the same as that for locoregional follow-up
(recommendation, expert agreement).
Rehabilitation after treatment for breast cancer
Rehabilitation should start before treatment with clear specific
information about possible post-treatment complications and how
they can be prevented and/or managed (standard). Functional
problems of arm or shoulder movement require early physiother-
apy (standard). Lymphoedema can be treated with physical
methods and systemic therapy (recommendation). Coumarin is
no longer indicated because of its toxicity and lack of efficacy
(standard).
Table 3 Management of patients with breast cancer with lymph node involvement (N+ve)
Premenopaual woman or p50 years old (Figure 16) Post menopausal woman or 450 years old (Figure 17)
ER+ve ER ve or unknown ER+ve or unknown ER ve
Standards Chemotherapy and tamoxifen Chemotherapy, no hormone
therapy
Tamoxifen No standard
Options Chemotherapy and ovarian suppression
7tamoxifen
Tamoxifen and chemotherapy Chemotherapy
Ovarian suppression 7tamoxifen (no
chemotherapy)
No adjuvant treatment
Recommendations Tamoxifen as adjuvant treatment in
premenopausal women can only be used
in association with chemotherapy
Independent of the hormone
receptor status of the tumour. High
dose chemotherapy is not
recommended except in the setting
of a randomised clinical trial (expert
agreement)
No chemotherapy if age and
performance status suggest poor
short-and/or long-term tolerance
(level of evidence: B)
The efficacy of the combination of ovarian
suppression and antioestrogens is unknown
(level of evidence: D) This combination
should be evaluated in randomised clinical
trials (expert agreement)
ER+ve¼presence of oestrogen receptors; ER ve¼absence of oestrogen receptors.
Table 4 Management of patients with breast cancer without lymph node involvement (N ve)
Premenopausl woman or p50 years old (Figure 18) Postmenopausal woman or 450 years old (Figure 19)
Risk of metastatic recurrence
a
No risk of
metastatic
recurrence
Risk of metastatic recurrence
a
No risk of
metastatic
recurrence
ER+ve ER ve or
unknown
ER+ve or
unknown
ER ve
Standards Chemotherapy and tamoxifen Chemotherapy no
hormonotherapy
(level of evidence: B)
No adjuvant
treatment
Tamoxifen No standard No adjuvant
treatment
Options Chemotherapy and ovarian
suppression, and tamoxifen
Tamoxifen if ER+ve Tamoxifen and chemotherapy Chemotherapy Tamoxifen if ER+ve
Ovarian suppression
7tamoxifen (no
chemotherapy)
No adjuvant
medical treatment
Recommendations Combination of tamoxifen and
chemotherapy in the setting of
randomised clinical trials (level
of evidence: B)
aPresence of one or more risk factors for metastatic recurrence. ER+ve¼presence of oestrogen receptors; ER ve¼absence of oestrogen receptors.
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routinely (recommendation). Sexual problems should be evaluated
and treated (recommendation). The need for contraception
and family planning advice should be discussed individually
taking into consideration each patient’s preference (recommenda-
tion).
Hormone replacement treatment for postmenopausal symptoms
should not be prescribed after treatment for breast cancer, except
in specific cases. The prescription of hormone replacement
treatment after breast cancer is being evaluated prospectively.
Nonhormonal treatments exist for the various symptoms (recom-
mendation).
Treatment after initial surgery
Lymph node involvement?
no
no
yes
yes no yes Premenopausal woman
or 50 years old
Premenopausal woman
or 50 years old
N+ve
Premenopausal woman
or 50 years old
Figure 16 
N−ve
Premenopausal woman
or 50 years old
Figure 18 
N−ve
Postmenopausal woman
or >50 years old
Figure 19
N+ve
Postmenopausal woman
or >50 years old
Figure 17
Figure 14 Operable tumour–adjuvant treatment.
N+ve
premenopausal woman or  50 years old 
yes no (or unknown)
ER+ve*?
Standards:
•  chemotherapy
•  no hormone therapy
Standard follow-up
Figure 21
Standard follow-up
Figure 21
*ER+ve, presence of oestrogen receptors.
Standard:
chemotherapy and tamoxifen
Options:
•   chemotherapy and ovarian
    suppression ± tamoxifen
•  ovarian ablation ± tamoxifen (without
    chemotherapy)
Figure 15 Operable tumour–adjuvant medical treatment (Nþve,
premenopausal woman or p50 years old).
N+ve
postmenopausal woman or >50 years 
no
       yes
 (or unknown)
ER+ve*?
Standard:
there is no standard
Options:
•  chemotherapy
•  no adjuvant medical
    treatment
Standard follow-up
Figure 21
Standard follow-up
Figure 21
*ER+ve , presence of oestrogen receptors.
Standard: 
tamoxifen
Option:
tamoxifen + chemotherapy
Figure 16 Operable tumour–adjuvant treatment (Nþve, postmeno-
pausal woman or 450 years old).
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during the management process (option). Social support, to
strengthen the psychological support, should be provided routi-
nely to help patients and their families (option). Patient
rehabilitation groups can contribute to the psychosocial support
of patients (option).
Management of patients with recurrent disease
Management of local recurrence after breast-conserving treatment
for breast cancer Local recurrence should be treated with surgery.
Radiotherapy should not be considered except in specific cases
(standard). The standard treatment is a simple total mastectomy
(standard). Immediate reconstruction can be considered (option).
If oestrogen receptors are present, additional hormone therapy is
recommended (recommendation).
Breast-conserving surgery can only be considered if the patient
refuses mastectomy or if mastectomy is technically impossible. In
this case, the patient should be informed of the high risk of
recurrent disease (recommendation). As the efficacy of additional
chemotherapy is unknown, this should only be considered in the
Standard follow-up
Figure 21
Standard follow-up
Figure 21
Standard follow-up
Figure 21
*ER+ve, presence of oestrogen receptors.
yes no (or unknown)
Presence of one or more risk 
factors for metastatic relapse?
yes
N−ve
premenopausal woman or 50 years old
ER+ve*?
no 
Standard:
no adjuvant medical treatment
Option:
tamoxifen if ER+ve* 
Standard:
chemotherapy and tamoxifen
Options:
•  chemotherapy and ovarian ablation ±
    tamoxifen
•  ovarian suppression ± tamoxifen
    (without chemotherpy)
Standards:
•  chemotherapy
•  no  hormone therapy
Figure 17 Operable tumour–adjuvant medical treatment (N ve,
premenopausal woman or p50 years old).
Local treatment after neoadjuvant treatment
Adjuvant treatment after neoadjuvant treatment
Standard:
there is no standard
Options:
•  conservative surgery + radiotherapy
•  modified radical mastectomy only
•  modified radical mastectomy + radiotherapy
•  radiotherapy only
•  radiotherapy + conservative surgery
•  radiotherapy + modified radical mastectomy 
 
Standard:
no systemic treatment
Option:
hormone therapy if ER+ve*
Standard follow-up
Figure 21
*ER+ve, presence of oestrogen receptors.
Figure 19 Palpable tumour, breast-conserving surgery not possible–
local treatment after neoadjuvant treatment.
no
ER+ve*?
yes
(or unknown)
Standard follow-up
Figure 21
Standard follow-up
Figure 21
Standard follow-up
Figure 21
*ER+ve, presence of oestrogen receptors.
N−ve
postmenopausal woman or >50 years old
Presence of one or more risk factors
for metastatic relapse?
yes
Standard:
no adjuvant treatment
Option:
tamoxifen if ER+ve*
Standard:
there is no standard
Options:
•  chemotherapy
•  no  adjuvant treatment
Standard:
tamoxifen
Option:
tamoxifen + chemotherapy
no
Figure 18 Operable tumour–adjuvant medical treatment (N ve,
postmenopausal woman or 450 years old).
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agreement).
Management of uncontrolled, isolated local recurrence (inflamma-
tory or locally advanced tumour) There is no standard (stan-
dard). Chemotherapy can be considered, followed if possible, by
local treatment that may or may not be curative (options). Local
treatment (surgery and/or radiotherapy) for symptom control can
also be considered (option).
Chemotherapy is appropriate for an inflammatory recurrence.
Radiotherapy can be considered if there are contraindications for
chemotherapy (option). When possible, mastectomy should be
performed for a locally advanced recurrence (option). If this is not
possible, chemotherapy or radiotherapy should be given with the
aim of making the lesion operable (option). Irrespective of the
treatments administered, the indications for additional medical
treatment will be the same as those for potentially curable isolated
recurrences (recommendation, expert agreement).
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